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Abstract
Bayes’ Theorem confers inherent limitations on the accuracy of
screening tests as a function of disease prevalence. We have shown in
previous work that a testing system can tolerate significant drops in
prevalence, up until a certain well-defined point known as the preva-
lence threshold, below which the reliability of a positive screening test
drops precipitously. Herein, we establish a mathematical model to
determine whether sequential testing overcomes the aforementioned
Bayesian limitations and thus improves the reliability of screening
tests. We show that for a desired positive predictive value of ρ that
approaches k, the number of positive test iterations ni needed is:
lim
ρ→k
ni =


ln
[
ρ(φ−1)
φ(ρ−1)
]
ln
[
a
1−b
]

 (1)
where ni = number of testing iterations necessary to achieve ρ,
the desired positive predictive value, a = sensitivity, b = specificity, φ
= disease prevalence and k = constant. Based on the aforementioned
derivation, we provide reference tables for the number of test iterations
needed to obtain a ρ(φ) of 50, 75, 95 and 99% as a function of various
levels of sensitivity, specificity and disease prevalence.
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1 Bayes’ Theorem
Bayes’ Theorem describes the probability of an event, based on prior
knowledge of conditions that are related to the event. As a principle, it
follows simply from the axioms of conditional probability. Mathematically
speaking, the equation translates to the conditional probability of an event
A given the presence of an event or state B. Indeed, as per Bayes’ Theorem,
the above relationship is equal to the probability of event B given event A,
multiplied by the ratio of independent probabilities of event A to event B.
Simply stated, the equation is written as follows:
P (A|B) =
P (B|A)P (A)
P (B)
(2)
Where A, B = events, P(A) and P(B) are the independent probabilities
of A and B, P (A|B) = probability of A given B is true and P (B|A) =
probability of B given A is true.
1.1 Proof of Bayes’ Theorem and its Relationship to ρ(φ)
Let us denote to independent events, A and B. The probability of events
A and B both occurring is denoted axiomatically as P (A∩B), and it equals
to the conditional probability of A, P(A), times the probability of B given
that A has occurred, P (B|A).
P (A ∩B) = P (A)P (B|A) (3)
Likewise, since we have pre-conditionally established that both events are
occurring, the index event order is commutative and could be switched to
obtain:
P (A ∩B) = P (B)P (A|B) (4)
Equating the above terms, we obtain the formal Bayes’ theorem as follows:
P (A|B) =
P (B|A)P (A)
P (B)
(5)
If we use T +/- as either a positive or negative test, and denote D +/-
as the presence or absence or disease then we can use Bayes’ theorem to
calculate the positive predictive value (PPV) of a screening test by asking
the following question: given a positive screening test result, what is the
probability that such individual does in fact have the disease in question?
In other words, what is the probability that a positive test is a true positive?
P (D + |T+) =
P (T + |D+)P (D+)
P (T+)
(6)
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Since the denominator in equation (5) represents the probability of hav-
ing a positive test regardless of context, then it follows logically that this
variable should equal to the sum of true positives and false positives.
Otherwise stated:
P (D + |T+) =
P (T + |D+)P (D+)
P (T + |D+)P (D+) + P (T + |D−)P (D−)
(7)
Furthermore, given that 1) the probability of having a positive test in
an individual with the disease is the sensitivity, and 2) the probability of
being disease-free is equal to the complement of the prevalence, and 3) the
false positive rate is equal to the complement of the specificity (true negative
rate), Bayes’ theorem provides a formal way to obtain the PPV, ρ(φ), as a
function of the prevalence φ, as follows:
ρ(φ) =
aφ
aφ+ (1− b)(1 − φ)
=
aφ
aφ+ bφ− b− φ+ 1
(8)
where ρ(φ) = PPV, a = sensitivity, b = specificity and φ = prevalence.
We have thus shown that the PPV, ρ(φ), is a function of prevalence, φ.
As the prevalence increases, the ρ(φ) also increases and vice-versa. By the
above equation, we obtain:
lim
φ→0
ρ(φ) = 0 (9)
lim
φ→1
ρ(φ) = 1 (10)
These limits denote the extremes of domain of the function ρ(φ), no-
tably [0,0], and [1,1]. Conversely, the negative predictive value, σ(φ) can be
denoted as:
σ(φ) =
b(1 − φ)
(1− a)φ+ b(1− φ)
(11)
The extreme limits of the domain of this function include [0,1] and [1,0].
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2 Prevalence Threshold
Let us define ε = a + b, the sum of a tests’ sensitivity and specificity.
Likewise, let us define the point of local extrema [φe, ρe], which denotes the
point of maximum curvature of the function ρ(φ) throughout the prevalence
spectrum as per equation (7). Practically speaking, φe tells us where the
sharpest turn, or change, in PPV as a function of prevalence occurs. In
cases of ε < 1 the sharp increase occurs at higher prevalence levels with low
PPV levels. Conversely, when ε > 1, as in the example below, the sharp
increase occurs at lower prevalence levels with high PPV levels [1].
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Figure 1. Sample test with ε > 1, where a = 0.98 and b = 0.97
2.1 How is φe determined?
Using differential calculus, as showcased in previous work by this author
[1], the formula for φe is defined as follows:
φe =
√
a (−b+ 1) + b− 1
(a + b− 1)
=
√
a (−b+ 1) + b− 1
(ε− 1)
(12)
This is the value of prevalence as function of sensitivity and specificity
where the point of local extrema φe is found. We denote this value of φ
as the prevalence threshold. By plugging φe into equation (3) we obtain its
corresponding ρe value. Note the inverse relationship between φe and ε.
φe ∼
1
ε
(13)
From the above relationship it is evident that even with values of sensi-
tivity and specificity whose sum nearly approaches its maximum value of 2,
there is a precipitous drop in PPV at low prevalence levels where the test’s
ρ is significantly hindered.
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3 Sequential Testing
Based on the aforementioned considerations, a problem arises. Since the
vast majority of medical conditions and disorders amenable to screening have
prevalences that are low in the general population, we deduce that a sig-
nificant proportion of positive screening tests conducted in modern practice
are false positives, which can bring about significant adverse administrative,
social, health and psychological consequences. As such, this insurmountable
fact about the nature of screening begs the question - is there anything to be
done to reduce the number of incorrect diagnoses that arise given the afore-
mentioned limitation?[3] Intuitively, as per equations (8), (9) and (10), the
development of novel screening tests with parameters such that ε ∼ 2 would
reduce the influence of prevalence in the equation [1]. But such endeavour
is costly and most often unattainable in the short term. Given human error,
variations in patient status/characteristics, sampling error and technological
limitations, the most intuitive method to ensure a correct diagnosis is made
on a patient is that of sequential, or repetitive, testing [5]. This phenomenon
is technically known as Bayesian updating. While this is a general term
that is used when any new information is added onto a system which was
previously analysed, it too applies when the same test is run serially to
improve its detection rate.
3.1 Conditional Probabilities
Conditional probabilities relate the likelihood of an occurrence given
that another related event has already taken place. That initial condition is
termed prior probability or in certain circumstances the pre-test probability.
When we account for those prior probabilities, and analyse a screening test
in that context, we obtain posterior probabilities. In general, with sequential
Bayesian estimation, one can use the previous posterior as the current prior
probability. As such, in the case of sequential testing where D represents the
presence of disease, T represents one initial positive test and TT represents
two consequent positive tests, Bayes’ theorem takes on the form:
P (D|T ) =
P (T |D)P (D)
P (T )
⇒ P (D|TT ) =
P (TT |D)P (D)
P (TT )
(14)
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4 General Derivation
The expression of equation (2) in generalized terms is the following:
P (D|T ) =
P (T |D)P (D)
P (T |D)P (D) + P (T |¬D)P (¬D)
(15)
where,
• P(D) is the prior probability, or the initial degree of belief in D
• P(¬D) is the corresponding initial degree of belief in ’not-D’, where
P(¬D) = 1-P(D)
• P(T|D) is the conditional probability or likelihood of T given that
proposition D is true
4.1 Bayesian updating formulation
Let T1, T2, ..., Tn denote n independent tests.
P (T1T2...Tn) = P (T1T2...Tn|D)P (D) + P (T1T2...Tn|¬D)P (¬D)
= P (T |D)nP (D) + P (T |¬D)nP (¬D)
= P (T |D)nP (D) + P (T |¬D)n(1− P (D))
Then, we can find our expression for P (D|T1, T2, ..., Tn).
P (D|T1T2...Tn) =
P (T1T2...Tn)|D)P (D)
P (T1T2...Tn)
=
P (T |D)nP (D)
P (T |D)nP (D) + P (T |¬D)n(1− P (D))
It thus follows that as n → ∞, at some iteration nx the above equation
converges as a function of P (T |D):
lim
n→∞
P (T |D)nP (D)
P (T |D)nP (D) + P (T |¬D)n(1− P (D))
=


1 if P (T |D) > 0.5
P (D) if P (T |D) = 0.5
0 if P (T |D) < 0.5
In terms of screening parameters, the above equation therefore becomes:
ρ(φ) =
anφ
anφ+ (1− b)n(1− φ)
=
anφ
anφ+ (1− b)n − φ(1− b)n
(16)
where n is the number of test iterations.
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To determine the number of tests needed to be carried out to obtain a
desired predictive value, we need to first isolate n as follows:
ρ(φ)anφ+ ρ(φ)(1− b)n(1− φ) = anφ (17)
Re-arranging the terms:
ρ(φ)anφ− anφ = −ρ(φ)(1 − b)n(1− φ) (18)
Factoring out the sensitivity a:
anφ[ρ(φ)− 1] = −ρ(φ)(1− b)n(1− φ) (19)
By the fraction rule of exponents:
an
(1− b)n
=
−ρ(φ)(1− φ)
φ[ρ(φ)− 1]
=
[
a
1− b
]n
(20)
Applying the natural logarithm to both sides:
ln
[
−ρ(φ)(1− φ)
φ[ρ(φ)− 1]
]
= ln
[
a
1− b
]n
(21)
Via the power rule, we obtain:
ln
[
−ρ(φ)(1− φ)
φ[ρ(φ)− 1]
]
= ln
[
a
1− b
]
n (22)
From the above relationship, we can isolate n:
n =
ln
[
−ρ(φ)(1−φ)
φ[ρ(φ)−1]
]
ln
[
a
1−b
] (23)
Finally, simplifying the expression:
n =
ln
[
φρ(φ)−ρ(φ)
φρ(φ)−φ
]
ln
[
a
1−b
] (24)
From this expression we can calculate the limit as ρ(φ) goes to 1, the
ultimate predictive value.
lim
ρ(φ)→1
n = lim
ρ(φ)→1
ln
[
φρ(φ)−ρ(φ)
φρ(φ)−φ
]
ln
[
a
1−b
] (25)
However, the limρ(φ)→1 n does not exist, since ln(φ-1/0) is undefined. In
clinical terms, this translates to the fact that in all but one special case where
disease prevalence φ is 1, no test can have a perfect positive predictive value.
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To overcome this limitation, we render the generalized form of the above
equation, and we denote ρ(φ) as ρ to obtain:
lim
ρ→k
ni =
ln
[
ρ(φ−1)
φ(ρ−1)
]
ln
[
a
1−b
] (26)
where ρ = desired positive predictive value to achieve, ni = number
of testing iterations necessary, a = sensitivity, b = specificity, φ = disease
prevalence and k = constant.
5 Properties of sequential testing
Since the natural logarithmic function is continuous and increasing through-
out its domain (0,∞+], it follows that as ln
[
a
1−b
]
increases, the number of
test iterations n needed to achieve a desired positive predictive value de-
creases as per equation (26). Tables 1-4 provide different reference values
of n as a function of the prevalence φ and the sensitivity and specificity for
a ρ of 99, 95, 75 and 50 %, respectively. The aforementioned relationship
holds for a number of sequential tests that are positive until the ni iteration
reaches the desired positive predictive value. For severe conditions whose
treatment is rather innocuous but whose potential consequences are severe,
a lower threshold to initiate treatment might be acceptable. Conversely, a
condition whose consequences are less severe but whose treatment may lead
to significant morbidity might benefit from a higher degree of diagnostic
certainty prior to initiating therapy or proceeding to an invasive diagnostic
test. Given the extremes of the domains of each predictive function as per
equations (8) and (11), and the fact that most conditions have a prevalence
well below 20% then it follows that if prior to reaching the desired positive
predictive value, a negative test result is obtained, the individual is more
likely to be disease-free, since σ(φ) >> ρ(φ) at a low prevalence of disease.
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Figure 2. Overlapping positive (blue) and negative (red) predictive value curves.
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5.1 Clinical Implications of ni
From the formula in (26), we learn that the number of iterations is
inversely proportional to the ratio of sensitivity over the complement of the
specificity.
ni ∼
1
ln
[
a
1−b
] (27)
However, the denominator of this equation is itself the natural logarithm
of a fraction. It follows that for certain values of sensitivity a and specificity
b, the ratio of [ a1−b ] is < 1. Since the natural logarithm of x follows the
following range properties:
ln(x) =


∈ C if x ≤ 0
undefined if x = 0
< 0 if 0 < x < 1
≥ 0 if x ≥ 1
(28)
We deduce that for values of a and b such that:
a < 1− b⇔ a+ b < 1 (29)
the denominator of the ni function will be negative and so will thus be ni.
Though it is highly unlikely that a test whose sensitivity and specificity
add to less than one would ever be used clinically [2], this idea does lead to
a fundamental understanding about the ni equation. What does it mean to
have a negative number of tests needed to achieve a given ρ(φ)? Clinically
it bears no meaning, since one would, by definition, need at least a single
test to have a positive result. It thus follows that for the above equation to
be of clinical use, we need to take its ceiling function [4], such that ⌈x⌉ is
the unique integer satisfying ⌈x⌉ - 1 < x < ⌈x⌉:
lim
ρ→k
ni =


ln
[
ρ(φ−1)
φ(ρ−1)
]
ln
[
a
1−b
]

 (30)
In practical terms, the ceiling function assigns the nearest positive integer
to a number [4]. For the case of screening tests, it implies that a whole rather
than a decimal number of tests (rounded to the nearest, higher integer) ought
to be performed.
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Figure 3. ni iteration plot as a function of sensitivity a, specificity b, and
disease prevalence φ for a positive predictive value of 95%.
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6 Addendum - Reference Tables
Prevalence (φ)
ln( a1−b) 0.02 0.05 0.07 0.1 0.15 0.2
0.50 16.97 15.08 14.36 13.58 12.66 11.96
1.00 8.49 7.54 7.18 6.79 6.33 5.98
1.50 5.66 5.03 4.79 4.53 4.22 3.99
2.00 4.24 3.77 3.59 3.40 3.16 2.99
2.50 3.39 3.02 2.87 2.72 2.53 2.39
3.00 2.83 2.51 2.39 2.26 2.11 1.99
3.50 2.42 2.15 2.05 1.94 1.81 1.71
4.00 2.12 1.88 1.80 1.70 1.58 1.50
4.50 1.89 1.68 1.60 1.51 1.41 1.33
5.00 1.70 1.51 1.44 1.36 1.27 1.20
Table 1: Reference table for the number of test iterations to obtain a ρ(φ)
of 99% as a function of sensitivity a, specificity b and disease prevalence φ.
To enhance the predictive value and perform a whole number of tests, round
up to the nearest integer using the ceiling function ⌈x⌉.
Prevalence (φ)
ln( a1−b ) 0.02 0.05 0.07 0.1 0.15 0.2
0.50 13.67 11.78 11.06 10.28 9.36 8.66
1.00 6.84 5.89 5.53 5.14 4.68 4.33
1.50 4.56 3.93 3.69 3.43 3.12 2.89
2.00 3.42 2.94 2.77 2.57 2.34 2.17
2.50 2.73 2.36 2.21 2.06 1.87 1.73
3.00 2.28 1.96 1.84 1.71 1.56 1.44
3.50 1.95 1.68 1.58 1.47 1.34 1.24
4.00 1.71 1.47 1.38 1.29 1.17 1.08
4.50 1.52 1.31 1.23 1.14 1.04 0.96
5.00 1.37 1.18 1.11 1.03 0.94 0.87
Table 2: Reference table for the number of test iterations to obtain a ρ(φ)
of 95% as a function of sensitivity a, specificity b and disease prevalence φ.
To enhance the predictive value and perform a whole number of tests, round
up to the nearest integer using the ceiling function ⌈x⌉.
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Prevalence (φ)
ln( a1−b) 0.02 0.05 0.07 0.1 0.15 0.2
0.50 9.98 8.09 7.37 6.59 5.67 4.97
1.00 4.99 4.04 3.69 3.30 2.83 2.48
1.50 3.33 2.70 2.46 2.20 1.89 1.66
2.00 2.50 2.02 1.84 1.65 1.42 1.24
2.50 2.00 1.62 1.47 1.32 1.13 0.99
3.00 1.66 1.35 1.23 1.10 0.94 0.83
3.50 1.43 1.16 1.05 0.94 0.81 0.71
4.00 1.25 1.01 0.92 0.82 0.71 0.62
4.50 1.11 0.90 0.82 0.73 0.63 0.55
5.00 1.00 0.81 0.74 0.66 0.57 0.50
Table 3: Reference table for the number of test iterations to obtain a ρ(φ)
of 75% as a function of sensitivity a, specificity b and disease prevalence φ.
To enhance the predictive value and perform a whole number of tests, round
up to the nearest integer using the ceiling function ⌈x⌉.
Prevalence (φ)
ln( a1−b) 0.02 0.05 0.07 0.1 0.15 0.2
0.50 7.78 5.89 5.17 4.39 3.47 2.77
1.00 3.89 2.94 2.59 2.20 1.73 1.39
1.50 2.59 1.96 1.72 1.46 1.16 0.92
2.00 1.95 1.47 1.29 1.10 0.87 0.69
2.50 1.56 1.18 1.03 0.88 0.69 0.55
3.00 1.30 0.98 0.86 0.73 0.58 0.46
3.50 1.11 0.84 0.74 0.63 0.50 0.40
4.00 0.97 0.74 0.65 0.55 0.43 0.35
4.50 0.86 0.65 0.57 0.49 0.39 0.31
5.00 0.78 0.59 0.52 0.44 0.35 0.28
Table 4: Reference table for the number of test iterations to obtain a ρ(φ)
of 50% as a function of sensitivity a, specificity b and disease prevalence φ.
To enhance the predictive value and perform a whole number of tests, round
up to the nearest integer using the ceiling function ⌈x⌉.
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